NEW YORK (WCMH) — New York Attorney General Eric Schneiderman is opening an antitrust investigation into the company that makes EpiPen.
Mylan Pharmaceuticals is facing heavy scrutiny from the public and politicians alike hiking the price of the life-saving drug by more than 600 percent last month. Schneiderman’s office says that a preliminary review by their office showed that the company potentially inserted anti-competitive terms into its sales contracts with New York school systems.
“No child’s life should be put at risk because a parent, school, or healthcare provider cannot afford a simple, life-saving device because of a drug-maker’s anti-competitive practices,” Schneiderman said in a press release. “If Mylan engaged in anti-competitive business practices, or violated antitrust laws with the intent and effect of limiting lower cost competition, we will hold them accountable. Allergy sufferers have enough concerns to worry about — the availability of life-saving medical treatment should not be one of them. I will bring the full resources of my office to this critical investigation.”
What others are clicking on: